Article Text

Download PDFPDF

1081 Vulvar cancer treatment between 2010 and 2019: the experience of a single Romanian cancer center
  1. V Galatan1,
  2. N Todor1,
  3. AT Kirsch-Mangu1,2,
  4. D Pop1,2,
  5. CI Trifan1,
  6. C Ordeanu1,
  7. R Bodea1,
  8. C Pop1,
  9. O Coza1,2,
  10. VM Nagy1,2,
  11. P Achimaş Cadariu1,2,
  12. FL Ignat1,2,
  13. DT Eniu1,2,
  14. AP Trăilă1,3,
  15. G Lazar1,2,
  16. Ş Hica1,
  17. AC Rancea1,2,
  18. IC Lisencu1,2,
  19. IC Vlad1,2 and
  20. A Trăilă3
  1. 1The Oncology Institute “Prof. Dr. Ion Chiricuţă” Cluj-Napoca, Cluj-Napoca, Romania
  2. 2University of Medicine and Farmacy “Iuliu Hatieganu” Cluj-Napoca, Romania, Cluj Napoca, Romania
  3. 3General Hospital “Humanitas” Cluj-Napoca, Romania, Surgery, Cluj Napoca, Romania


Introduction/Background*The purpose of this study was to evaluate 5-year overall survival (OS), disease free survival (DFS) and local control (LC) for patients diagnosed with primary vulvar cancer and treated at Institute of Oncology “Prof.Dr.Ion Chiricuta” Cluj-Napoca, Romania.

Methodology Between 2010 and 2019 a number of 306 patients with vulvar cancer were treated in our institution, from which we included in this retrospective study 233 patients with squamous cell vulvar cancer; based on FIGO staging: 19 (8.2%) patients were stage 0, 115 (49.4%) stage I, 17 (7.3%) stage II, 66 (28.3%) stage III and 16 (6.8%) stage IV. 146 patients (62.7%) underwent exclusive surgery, 70 (30%) had surgery combined with adjuvant treatment and 17 (7.3%) with palliative treatment. After these therapeutic modalities patients were followed for a median of 47.1 months (minimum 4.5 months and maximum 122.4 months).

Result(s)*The median age was 68 years (minimum of 28 years and maximum of 89 years) and median number of cases per year was 23.3. The OS by stage of disease was 95%, 84%, 72%, 37% respectively 12% for stage 0, I, II, III respectively IV (p<0.01). The OS for patients treated with exclusive surgery, surgery combined with adjuvant treatment respectively palliative treatment was 74%, 61% respectively 12% (p<0.01). 150 (64.4%) patients had lymphadenectomy with a median number of 8 lympnodes (minimum 0, maximum 47); patient with negative lymph nodes and without extracapsular effraction (EC) had OS, DFS and LC significantly improved (p<0.01). DSF for stage I respectively II was 67% respectively 62%; LC for stage I respectively stage II was 68% and 62% (p<0.01). Patients with exclusive surgery and surgery combined with adjuvant treatment, had a DSF and LC significantly increased (p<0.01) in comparison with palliative treatment.

Abstract 1081 Figure 1

Disease free survival based on age groups

Abstract 1081 Figure 2

Overall survival FIGO stages

Conclusion*Squamous cell vulvar cancer is a rare cancer in our institution. Surgery remains the best treatment modality for early stages of the disease (stage I and II) and gives high survival rate, DFS and LC, among negative lymph nodes involvement and without extracapsular effraction. For better outcomes there is need for treatment personalization according to new international protocols.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.